NCT07174544

Mobile Self-Management Program for Stress Reduction in Young Adults

Completed NA Results posted Last updated 8 January 2026

What this trial tests

NA trial testing Mobile Self-Management Program integrated with Positive Psychology and Behavioral Activation in Stress (Psychology) in 211 participants. Completed in 30 August 2025.

Timeline

1 September 2023

Primary endpoint
31 December 2024

30 August 2025

Quick facts

Lead sponsor	The Catholic University of Korea
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	211
Start date	1 September 2023
Primary completion	31 December 2024
Estimated completion	30 August 2025
Sites	1 location across South Korea

Drugs / interventions tested

• Mobile Self-Management Program integrated with Positive Psychology and Behavioral Activation

Conditions studied

• Stress (Psychology) — all drugs for Stress (Psychology) →

Sponsor

The Catholic University of Korea

Who can join

Adults 19 to 34, any sex, with Stress (Psychology). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Stress at Baseline Secondary · Baseline

Stress was measured using the Korean version of the Perceived Stress Scale - 10 items (PSS-10). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress. Although the scale does not provide a standardized cut-off, prior studies have used a score of 14 or higher to define moderate-to-high levels of stress, and this threshold was applied in the present study.

Group	Value	95% CI
Intervention Group	22.64	± 5.82
Wait-list Control	19.76	± 3.64

Stress at Week 2 Secondary · Week 2

Stress was measured using the Korean version of the Perceived Stress Scale - 10 items (PSS-10). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress. Although the scale does not provide a standardized cut-off, prior studies have used a score of 14 or higher to define moderate-to-high levels of stress, and this threshold was applied in the present study.

Group	Value	95% CI
Intervention Group	20.57	± 5.78
Wait-list Control	19.00	± 3.98

Stress at Week 4 Secondary · Week 4

Stress was measured using the Korean version of the Perceived Stress Scale - 10 items (PSS-10). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress. Although the scale does not provide a standardized cut-off, prior studies have used a score of 14 or higher to define moderate-to-high levels of stress, and this threshold was applied in the present study.

Group	Value	95% CI
Intervention Group	20.08	± 6.62
Wait-list Control	18.71	± 4.00

Depression (PHQ-9) at Baseline Secondary · Baseline

Depression was assessed using the Korean version of the Patient Health Questionnaire-9 items (PHQ-9). The PHQ-9 consists of nine items rated on a 4-point Likert scale (0 = not at all to 3 = nearly every day), assessing symptom frequency over the past two weeks. The total score ranges from 0 to 27, with higher scores indicating more severe depression.

Group	Value	95% CI
Intervention Group	10.21	± 5.89
Wait-list Control	9.24	± 5.42

Depression (PHQ-9) at Week 2 Secondary · Week 2

Depression was assessed using the Korean version of the Patient Health Questionnaire-9 items (PHQ-9). The PHQ-9 consists of nine items rated on a 4-point Likert scale (0 = not at all to 3 = nearly every day), assessing symptom frequency over the past two weeks. The total score ranges from 0 to 27, with higher scores indicating more severe depression.

Group	Value	95% CI
Intervention Group	8.34	± 5.44
Wait-list Control	8.51	± 5.63

Depression (PHQ-9) at Week 4 Secondary · Week 4

Depression was assessed using the Korean version of the Patient Health Questionnaire-9 items (PHQ-9). The PHQ-9 consists of nine items rated on a 4-point Likert scale (0 = not at all to 3 = nearly every day), assessing symptom frequency over the past two weeks. The total score ranges from 0 to 27, with higher scores indicating more severe depression.

Group	Value	95% CI
Intervention Group	7.72	± 5.91
Wait-list Control	7.95	± 5.36

Stress at Week 8 Primary · Week 8

Stress was measured using the Korean version of the Perceived Stress Scale - 10 items (PSS-10). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress. Although the scale does not provide a standardized cut-off, prior studies have used a score of 14 or higher to define moderate-to-high levels of stress, and this threshold was applied in the present study.

Group	Value	95% CI
Intervention Group	19.41	± 6.20
Wait-list Control	18.35	± 4.05

Depression (PHQ-9) at Week 8 Secondary · Week 8

Depression was assessed using the Korean version of the Patient Health Questionnaire-9 items (PHQ-9). The PHQ-9 consists of nine items rated on a 4-point Likert scale (0 = not at all to 3 = nearly every day), assessing symptom frequency over the past two weeks. The total score ranges from 0 to 27, with higher scores indicating more severe depression.

Group	Value	95% CI
Intervention Group	8.37	± 6.38
Wait-list Control	7.69	± 5.50

Anxiety (GAD-7) at Baseline Secondary · Baseline

Anxiety was measured using the Korean version of the Generalized Anxiety Disorder-7 items (GAD-7). The GAD-7 consists of seven items rated on a 4-point Likert scale (0 = not at all to 3 = nearly every day), assessing symptom frequency over the past two weeks. The total score ranges from 0 to 21, with higher scores indicating more severe anxiety.

Group	Value	95% CI
Intervention Group	8.20	± 5.75
Wait-list Control	7.68	± 4.88

Anxiety (GAD-7) at Week 2 Secondary · Week 2

Anxiety was measured using the Korean version of the Generalized Anxiety Disorder-7 items (GAD-7). The GAD-7 consists of seven items rated on a 4-point Likert scale (0 = not at all to 3 = nearly every day), assessing symptom frequency over the past two weeks. The total score ranges from 0 to 21, with higher scores indicating more severe anxiety.

Group	Value	95% CI
Intervention Group	6.88	± 5.65
Wait-list Control	7.13	± 5.23

Anxiety (GAD-7) at Week 4 Secondary · Week 4

Anxiety was measured using the Korean version of the Generalized Anxiety Disorder-7 items (GAD-7). The GAD-7 consists of seven items rated on a 4-point Likert scale (0 = not at all to 3 = nearly every day), assessing symptom frequency over the past two weeks. The total score ranges from 0 to 21, with higher scores indicating more severe anxiety.

Group	Value	95% CI
Intervention Group	6.43	± 5.61
Wait-list Control	7.03	± 5.21

Anxiety (GAD-7) at Week 8 Secondary · Week 8

Anxiety was measured using the Korean version of the Generalized Anxiety Disorder-7 items (GAD-7). The GAD-7 consists of seven items rated on a 4-point Likert scale (0 = not at all to 3 = nearly every day), assessing symptom frequency over the past two weeks. The total score ranges from 0 to 21, with higher scores indicating more severe anxiety.

Group	Value	95% CI
Intervention Group	7.63	± 6.11
Wait-list Control	6.36	± 4.87

Sponsor's own description

The goal of this clinical trial is to learn if a mobile self-management program that combines Positive Psychology (PP) and Behavioral Activation (BA) helps reduce stress in young adults in South Korea. It will also examine how the program affects depression, anxiety, and resilience.

The main questions it aims to answer are:

Does the program lower stress levels in young adults with high stress?

Does the program improve other aspects of mental health, such as depression, anxiety, and resilience?

Researchers will compare the mobile program to a wait-list control group to see if the program works to improve stress management.

Participants will:

Be randomly assigned to either the program group or a wait-list control group

Use the mobile program for 4 weeks with guided activities, followed by 4 weeks of self-directed use

Complete surveys at the start, week 2, week 4, and week 8 about their stress, depression, anxiety, and resilience

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.